A. Schott

发表

Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance

Dafydd G. Thomas, D. Hayes, J. Rae, 2016, Molecular oncology.

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

Javed Siddiqui, Arul M Chinnaiyan, Pankaj Vats, 2013, Nature Genetics.

Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500.

Robert B Livingston, Gordan Srkalovic, Brian Leyland-Jones, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme

K. Griffith, D. Hayes, J. Rae, 2006, Cancer Chemotherapy and Pharmacology.

Spatial registration of temporally separated whole breast 3D ultrasound images.

P. Carson, J. Fowlkes, M. Roubidoux, 2009, Medical physics.

Adjuvant chemotherapy for elderly women with hormone receptor-positive breast cancer: an old(er) problem.

D. Hayes, A. Schott, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of an automatic registration-based algorithm for direct measurement of volume change in tumors.

C. Meyer, P. Bland, T. Chenevert, 2012, International journal of radiation oncology, biology, physics.

Predictors of recovery of ovarian function during aromatase inhibitor therapy.

M. Banerjee, D. Hayes, D. McConnell, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer.

J. Niland, S. Edge, R. Theriault, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

The impact of breast reconstruction on the delivery of chemotherapy

J. Niland, S. Edge, R. Theriault, 2010, Cancer.

Abstract S5-06: Randomized, placebo-controlled trial of duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) in early stage breast cancer (SWOG S1202)

C. Moinpour, J. Unger, L. Fehrenbacher, 2017 .

Bcl-XL protects cancer cells from p53-mediated apoptosis.

M. Clarke, G. Núñez, A. Schott, 1995, Oncogene.

Monitoring serial changes in circulating human breast cancer cells in murine xenograft models.

G. Dontu, M. Wicha, D. Hayes, 2008, Cancer research.

Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps

Michael S. Goldberg, R. Wysocki, Michael S Goldberg, 2016, Science Translational Medicine.

Reply to J. Perlmutter et al and D. Yee et al

D. Hayes, A. Schott, 2012 .

Modeling the Relationship between Progression-Free Survival and Overall Survival: The Phase II/III Trial

M. LeBlanc, L. Baker, A. Schott, 2013, Clinical Cancer Research.

Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622

G. Hortobagyi, C. Moinpour, W. Barlow, 2016, Breast Cancer Research and Treatment.

Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.

K. Stelzer, F. Kabbinavar, C. Russell, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms.

A. Chinnaiyan, Dafydd G. Thomas, S. Tomlins, 2018, Cancer research.

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)

D. Amadori, M. Moroni, N. Ibrahim, 2021, Breast Cancer Research and Treatment.

Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2–Negative Metastatic Breast Cancer

M. Wicha, J. Reuben, R. Perez, 2017, Clinical Cancer Research.

Abstract P3-11-16: S0800: Nab-paclitaxel, doxorubicin, cyclophosphamide, and pegfilgrastim with or without bevacizumab in treating women with inflammatory or locally advanced breast cancer (NCI CDR0000636131)

E. Perez, G. Hortobagyi, L. Pusztai, 2015 .

Ado-Trastuzumab Emtansine-Induced Pulmonary Toxicity: A Single-Institution Retrospective Review

K. Kidwell, A. Schott, H. Egloff, 2018, Case Reports in Oncology.

Abstract S5-07: SWOG S0500 – A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment

E. Winer, B. Leyland-Jones, R. Livingston, 2013 .

Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430.

G. Hortobagyi, R. Livingston, W. Barlow, 2012, The oncologist.

Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study.

R. Jagsi, K. Griffith, W. Woodward, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Envisioning clinical trials as complex interventions

T. Skolarus, L. Damschroder, A. Sales, 2022, Cancer.

A case of thigh swelling in a patient with metastatic breast cancer receiving combination chemotherapy

A. Schott, 2006 .

Rapid-onset endothelial dysfunction with adriamycin: evidence for a dysfunctional nitric oxide synthase

R. Brook, S. Rajagopalan, J. Joseph, 2003, Vascular medicine.

The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.

P. Watkins, M. Strawderman, L. Baker, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.

G. Hortobagyi, L. Pusztai, D. Tripathy, 2021, The New England journal of medicine.

SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less.

G. Hortobagyi, C. Moinpour, S. Ramsey, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Dose Escalation Trial of Gemcitabine with Radiotherapy for Breast Cancer in the Treatment of Unresectable Chest Wall Recurrences

J. Hayman, M. Schipper, L. Pierce, 2004, The breast journal.

Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure.

J. Griggs, D. Hayes, K. Kidwell, 2019, Pharmacogenomics.

ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.

Daniel Birnbaum, Max S Wicha, D. Birnbaum, 2007, Cell stem cell.

Pilot study of duloxetine for treatment of aromatase inhibitor‐associated musculoskeletal symptoms

J. Griggs, M. Banerjee, M. Wicha, 2011, Cancer.

Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors

Ian Krop, Jaya Paranilam, Max S Wicha, 2013, Clinical Cancer Research.

Integrative Clinical Genomics of Metastatic Cancer

Robert J. Lonigro, Daniel F. Hayes, Arul M. Chinnaiyan, 2017, Nature.

Abstract OT2-3-01: Phase Ib pilot study to evaluate reparixin in combination with chemotherapy with weekly paclitaxel in patients with HER-2 negative metastatic breast cancer (MBC)

M. Wicha, J. Reuben, M. Cristofanilli, 2012 .

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors

David C. Smith, A. Chinnaiyan, Xuhong Cao, 2021, JAMA oncology.

Prediction of postchemotherapy ovarian function using markers of ovarian reserve.

Mousumi Banerjee, Daniel McConnell, Daniel F Hayes, 2014, The oncologist.

Genome Medicine in Cancer: What's in a Name?

C. Perou, D. Hayes, A. Schott, 2015, Cancer research.

Personalized Medicine: Genomics Trials in Oncology.

Daniel F Hayes, D. Hayes, A. Schott, 2015, Transactions of the American Clinical and Climatological Association.

Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer: clinical validity but not utility.

D. Hayes, A. Schott, N. L. Henry, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer Therapy : Clinical Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors

Jenny C. Chang, G. Dontu, M. Wicha, 2013 .

Defining the benefits of neoadjuvant chemotherapy for breast cancer.

Daniel F Hayes, D. Hayes, A. Schott, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pathologic Features of Breast Cancer Associated With Complete Response to Neoadjuvant Chemotherapy: Importance of Tumor Necrosis

K. Griffith, C. Kleer, A. Schott, 2005, The American journal of surgical pathology.

Neoadjuvant Chemotherapy: What Are the Benefits for the Patient and for the Investigator?

Daniel F Hayes, D. Hayes, A. Schott, 2015, Journal of the National Cancer Institute. Monographs.

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

Daniel F. Hayes, Arul M. Chinnaiyan, Heather A. Parsons, 2015, Clinical Cancer Research.

Adjuvant Trastuzumab Benefit in Patients Diagnosed With Triple-Positive Breast Cancer.

A. Schott, 2016, JAMA oncology.

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer

E. Perez, G. Hortobagyi, L. Pusztai, 2016, Breast Cancer Research and Treatment.

Activating ESR 1 mutations in hormone-resistant metastatic breast cancer

K. Pienta, A. Chinnaiyan, J. Roberts, 2013 .

Sentinel Lymph Node Biopsy Performed After Neoadjuvant Chemotherapy is Accurate in Patients with Documented Node-Positive Breast Cancer at Presentation

L. Newman, A. Chang, A. Nees, 2007, Annals of Surgical Oncology.

Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.

C. Moinpour, J. Unger, L. Fehrenbacher, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of estrogen depletion on pain sensitivity in aromatase inhibitor-treated women with early-stage breast cancer.

David A. Williams, K. Griffith, S. Harte, 2014, The journal of pain : official journal of the American Pain Society.

Fever and neutropenia clinical practice guidelines.

L. Elting, G. Noskin, G. Marcucci, 2004, Journal of the National Comprehensive Cancer Network : JNCCN.

Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy.

Lang Li, D. Hayes, T. Skaar, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Factors influencing the use of extended adjuvant endocrine therapy

J. Griggs, D. Hayes, K. Kidwell, 2019, Breast Cancer Research and Treatment.

Clinical predictors of long-term survival in HER2-positive metastatic breast cancer

S. Merajver, J. Griggs, M. Wicha, 2016, Breast Cancer Research and Treatment.

Development ofCirculatingTumorCell-Endocrine Therapy Index in Patients with Hormone Receptor – Positive Breast Cancer

Dafydd G. Thomas, D. Hayes, J. Rae, 2015 .

Development of Circulating Tumor Cell-Endocrine Therapy Index in Patients with Hormone Receptor–Positive Breast Cancer

K. Griffith, Dafydd G. Thomas, D. Hayes, 2014, Clinical Cancer Research.

Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy

J. Griggs, D. Hayes, E. Smith, 2018, Clinical Cancer Research.

Multi-Site Clinical Evaluation of DW-MRI as a Treatment Response Metric for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Bing Ma, Craig J. Galbán, Colleen H. Neal, 2015, PloS one.

Image registration for quantitative parametric response mapping of cancer treatment response.

Ryan Chamberlain, Alnawaz Rehemtulla, Benjamin Lemasson, 2014, Translational oncology.

Leukemia and lymphoma

A. Schott, 1997 .

Clinical and Radiologic Assessments to Predict Breast Cancer Pathologic Complete Response to Neoadjuvant Chemotherapy

Mark A. Helvie, Marilyn A. Roubidoux, Chintana Paramagul, 2005, Breast Cancer Research and Treatment.

Improving the delivery of team-based survivorship care after primary breast cancer treatment through a multi-level intervention: a pilot randomized controlled trial

J. Griggs, S. Hawley, J. Ayanian, 2021, Breast Cancer Research and Treatment.

SWOG S 0800 ( NCI CDR 0000636131 ) : addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response ( pCR ) rates in inflammatory or locally advanced breast cancer

E. Perez, G. Hortobagyi, L. Pusztai, 2016 .

Sonographic Evaluation of Early‐Stage Breast Cancers That Undergo Neoadjuvant Chemotherapy

Paul L Carson, Timothy D Johnson, Marilyn A Roubidoux, 2005, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

Axillary Staging Prior to Neoadjuvant Chemotherapy for Breast Cancer: Predictors of Recurrence

L. Newman, A. Chang, A. Nees, 2008, Annals of Surgical Oncology.

Sentinel node biopsy prior to neoadjuvant chemotherapy.

A. Chang, L. Pierce, D. Hayes, 2003, American journal of surgery.

Prospective Early Response Imaging Biomarker for Neoadjuvant Breast Cancer Chemotherapy

Bradford A Moffat, Alnawaz Rehemtulla, Thomas L Chenevert, 2007, Clinical Cancer Research.

The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare Cancers.

R. Kurzrock, C. Verschraegen, A. Schott, 2015, Seminars in oncology.

TBCRC 024 Initial Results: A Multicenter Phase 1 Study of Veliparib Administered Concurrently With Chest Wall and Nodal Radiation Therapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer

R. Jagsi, K. Griffith, J. Bellon, 2015 .

Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ

L. Newman, M. Helvie, D. Hayes, 2006, Cancer.